Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Surrozen, Inc./DESRZN · Entity 6092 | Director | May 13, 2026 | May 14, 2026 |
| Tango Therapeutics, Inc.TNGX · Entity 1497 | Director | June 05, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Surrozen, Inc./DE
Report date May 13, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.14 · Expires 2036-05-12 | Direct | 5,550 |
Reported balance
After 2026-05-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-13 · Grant · Acquired 5,550 · Balance 5,550 F1: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director.
Tango Therapeutics, Inc.
Report date June 05, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,500 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 4,000 · Balance 41,500 F1: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in their entirety on the earlier of: (i) June 5, 2027 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.22 · Expires 2036-06-05 | Direct | 25,000 |
Reported balance
After 2026-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-05 · Grant · Acquired 25,000 · Balance 25,000 F2: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in their entirety on the earlier of: (i) June 5, 2027 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
F2: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 8, 2026 21:55 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $20.22 | $0.00 |
DisclosureSEC source: 0001193125-26-262191 · ownership.xml · derivative · entry 2 Rothenberg Mace · CIK 0001873988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2036-06-05 F2 · derivative.exercise_date: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 21:55 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-262191 · ownership.xml · nonDerivative · entry 1 Rothenberg Mace · CIK 0001873988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,500 F1 · shares: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in their entirety on the earlier of: (i) June 5, 2027 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| May 13, 2026 Filed May 14, 2026 21:01 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | GrantDirector Stock Option (right to buy) · Derivative | 5,550 | $0.00 Strike: $30.14 | $0.00 |
DisclosureSEC source: 0001193125-26-224286 · ownership.xml · derivative · entry 1 Rothenberg Mace · CIK 0001873988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,550 Underlying: Common Stock · 5,550 shares Expires 2036-05-12 F1 · derivative.exercise_date: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 21:47 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0000950170-25-083907 · ownership.xml · derivative · entry 2 Rothenberg Mace · CIK 0001873988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2035-06-05 F2 · derivative.exercise_date: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 21:47 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-083907 · ownership.xml · nonDerivative · entry 1 Rothenberg Mace · CIK 0001873988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 F1 · shares: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in its entirety on the earlier of: (i) June 5, 2026 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| May 14, 2025 Filed May 15, 2025 21:22 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | GrantOption (right to buy) · Derivative | 1,333 | $0.00 Strike: $6.50 | $0.00 |
DisclosureSEC source: 0001593968-25-000610 · primary_01.xml · derivative · entry 1 Rothenberg Mace · CIK 0001873988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,333 Underlying: Common Stock · 1,333 shares Expires 2035-05-14 F1 · derivative.exercise_date: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director. Read SEC document |
| November 18, 2024 Filed Nov 19, 2024 00:20 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | PurchaseCommon Stock | 10,000 | $3.78 | $37,800.00 |
DisclosureSEC source: 0000950170-24-128163 · ownership.xml · nonDerivative · entry 2 Rothenberg Mace · CIK 0001873988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,250 Read SEC document |
| November 14, 2024 Filed Nov 19, 2024 00:20 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | PurchaseCommon Stock | 10,000 | $3.62 | $36,200.00 |
DisclosureSEC source: 0000950170-24-128163 · ownership.xml · nonDerivative · entry 1 Rothenberg Mace · CIK 0001873988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,250 Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 00:30 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | GrantOption (right to buy) · Derivative | 1,333 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001593968-24-000832 · primary_01.xml · derivative · entry 1 Rothenberg Mace · CIK 0001873988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,333 Underlying: Common Stock · 1,333 shares Expires 2034-06-05 F1 · derivative.exercise_date: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 21:17 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $7.41 | $0.00 |
DisclosureSEC source: 0000950170-24-070884 · ownership.xml · derivative · entry 2 Rothenberg Mace · CIK 0001873988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2034-06-05 F2 · derivative.exercise_date: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year beginning on July 5, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 21:17 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-070884 · ownership.xml · nonDerivative · entry 1 Rothenberg Mace · CIK 0001873988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,250 F1 · shares: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in its entirety on the earlier of: (i) June 5, 2025 and (iii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| June 06, 2023 Filed Jun 9, 2023 01:40 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.55 | $0.00 |
DisclosureSEC source: 0000899243-23-015020 · doc4.xml · derivative · entry 2 Rothenberg Mace · CIK 0001873988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-06-06 F2 · derivative.exercise_date: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year beginning on July 6, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| June 06, 2023 Filed Jun 9, 2023 01:40 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-015020 · doc4.xml · nonDerivative · entry 1 Rothenberg Mace · CIK 0001873988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 F1 · shares: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in its entirety on the earlier of: (i) June 6, 2024 and (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| May 18, 2023 Filed May 19, 2023 20:17 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | GrantOption (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001593968-23-000842 · primary_01.xml · derivative · entry 1 Rothenberg Mace · CIK 0001873988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-05-18 Read SEC document |
| June 08, 2022 Filed Jun 28, 2022 20:27 UTC | Tango Therapeutics, Inc. TNGX · Entity 1497 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0000899243-22-024398 · doc4.xml · derivative · entry 1 Rothenberg Mace · CIK 0001873988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year from June 8, 2022, subject to the Reporting Person's continuous service on the board of directors as of each such vesting date. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:50 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | GrantOption (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.79 | $0.00 |
DisclosureSEC source: 0001593968-22-001110 · primary_01.xml · derivative · entry 1 Rothenberg Mace · CIK 0001873988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Surrozen, Inc. Common Stock · 20,000 shares Expires 2032-06-07 F1 · derivative.exercise_date: The options fully vest and become exercisable on the one-year anniversary of the grant date, subject to the reporting person's continuous service as a director. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.